Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors

Cancer Research

Volumn 57, Issue 21, 1997, Pages 4956-4964

  Fulda, Simone ^a   Friesen, Claudia ^a   Los, Marek ^a   Scaffidi, Carsten ^b   Mier, Walter ^b   Benedict, Mary ^c   Nuñez, Gabriel ^c   Krammer, Peter H ^b   Peter, Marcus E ^b   Debatin, Klaus Michael ^a,d  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETULIC ACID; CASPASE; DOXORUBICIN; FAS ANTIGEN; INTERLEUKIN 1BETA CONVERTING ENZYME; PROTEIN BCL 2; PROTEIN P53; PROTEINASE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; ENZYME ACTIVATION; ETIOLOGY; EWING SARCOMA; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NEUROECTODERM TUMOR; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CASPASE 1; CYSTEINE ENDOPEPTIDASES; DNA FRAGMENTATION; DNA, NEOPLASM; DOXORUBICIN; HUMANS; MITOCHONDRIA; NEOPLASM PROTEINS; NEUROBLASTOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; TRITERPENES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030815250     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
2. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K-M. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med., 2: 574-577, 1996.
3. Fulda, S., Sieverts, H., Friesen, C., Herr, I., and Debatin, K. M. The CD95 (APO-1/ Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res., 57: 3823-3829, 1997.
4. Oehm, A., Behrmann, I., Falk, W., Pawlita, M., Maier, G., Klas, C., Li-Weber, M., Richards, S., Dhein, J., Trauth, B. C., Ponstingl, H., and Krammer, P. H. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. J. Biol. Chem., 267: 10709-10715, 1992.
5. Leithäuser, F., Dhein, J., Mechtersheimer, G., Koretz, K., Brüderlein, S., Henne, C., Schmidt, A., Debatin, K-M., Krammer, P. H., and Möller, P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest., 69: 415-429, 1993.
6. Debatin, K-M. Disturbances of the CD95 (APO-1/Fas) system in disorders of lymphohaematopoietic cells. Cell Death Differ., 3: 185-189, 1996.
7. Nagata, S. Apoptosis by death factor. Cell, 88: 355-365, 1997.
8. Peter, M. E., Kischkel, F. C., Hellbrandt, S., Chinnaiyan, A. M., Krammer, P. H., and Dixit, V. M. CD95 (APO-1/Fas)-associating signaling proteins. Cell Death Differ., 3: 161-170, 1996.
9. Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Krammer, P. H., Peter, M. E., and Dixit, V. M. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell, 85: 817-827, 1996.
10. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V., and Wallach, D. Involvement of MACH, a novel MORT-1/FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death. Cell, 85: 803-815, 1996.
11. Kischkel, F. C., Hellbrandt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P. H., and Peter, M. E. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins (CAP) form a death-inducing signaling complex (DISC) with the receptor. EMBO J., 14: 5579-5588, 1995.
12. Medema, J. P., Scaffidi, C., Kischkel, F. C., Shevchenko, A., Mann. M., Krammer, P. H., and Peter, M. E. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J., 16: 2794-2804, 1997.
13. Srinivasula, S. M., Ahmad, M., Fernandes-Alnemri, T., Liwack, G., and Alnemri, E. S. Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc. Natl. Acad. Sci. USA, 93: 14486-14491, 1996.
14. Muzio, M., Salvesen, G. S., and Dixit, V. M. FLICE induced apoptosis in a cell-free system. J. Biol. Chem., 272: 2952-2956, 1997.
15. Suda, T., Takahashi, T., Golstein, P., and Nagata, S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell, 75: 1169-1178, 1993.
16. Tanaka, M., Suda, T., Takahashi, T., and Nagata, S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J., 14: 1129-1135, 1995.
17. Kroemer, G., Zamzami, N., and Susin, S. A. Mitochondrial control of apoptosis. Immunol. Today, 18: 44-51, 1997.
18. Zamzami, N., Susin, S. A., Marchetti, P., Hirsch, T., Gomez-Monterrey, I., Castedo, M., and Kroemer, G. Mitochondrial control of nuclear apoptosis. J. Exp. Med., 183: 1533-1544, 1996.
19. L antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res., 57: 62-67, 1997.
20. Yang, E., and Korsmeyer, S. J. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood, 88: 386-401, 1996.
21. L forms an ion channel in synthetic lipid membranes. Nature (Lond.), 385: 353-357, 1997.
22. Schendel, S. L., Xie, Z., Montal, M. O., Matsuyama, S., Montal, M., and Reed, J. C. Channel formation by antiapoptotic protein Bcl-2. Proc. Nutl. Acad. Sci. USA, 94: 5113-5118, 1997.
23. Berthold, F., Burdach, S., Kremens, B., Lampert, F., Niethammer, D., Riehm, H., Ritter, J., Treuner, J., Utsch, S., and Zieschang, J. The role of chemotherapy in the treatment of children with neuroblastoma stage IV: the GPO (German Pediatric Oncology Society experience). Klin. Paediatr., 202: 262-269, 1990.
24. Pisha, E., Chai, H., Lee, I. S, Chagwedera, T. E., Farnsworth, N. R., Cordell, G. A., Beecher, C. W., Fong, H. H., Kinghorn, A. D., Brown, D. M., Wani, M. C., Wall, M. E., Hieken, T. I., Das Gupta, T. K., and Pezzuto, J. M. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat. Med., 1: 1046-1051, 1995.
25. Dole, M., Nuñez, G., Merchant, A. K., Maybaum, J., Rode, C. K., Bloch, C. A., and Castle, V. P. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res., 54: 3253-3259, 1994.
26. L is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res., 55: 2576-2582, 1995.
27. Trauth, B. C., Klas, C., Peter, A. M. J., Matz, S., Möller, P., Falk, W., Debatin, K-M., and Krammer, P. H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science (Washington DC), 245: 301-305, 1989.
28. Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., and Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods, 139: 271-279, 1991.
29. Koopman, G., Reutelingsperger, C. P. M., Kuijten, G. A. M., Keehnen, R. M. J., Pals, S. T., and van Oers, M. H. J. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 84: 1415-1420, 1994.
30. Wu, Z., Schwartz, E., Seeger, R., and Ladisch, S. Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res., 46: 440-443, 1986.
31. Dhein, J., Walczak, H., Bäumler, C., Debatin, K-M., and Krammer, P. H. Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature (Lond.), 373: 438-441, 1995.
32. Los, M., Van de Craen, M., Penning, L. C., Schenk, H., Westendorp, M., Baeuerle, P. A., Droege, W., Krammer, P. H., Fiers, W., and Schulze-Osthoff, K. Requirement of an ICE/Ced-3 protease for Fas/APO-1-mediated apoptosis. Nature (Lond.), 375: 81-83, 1995.
33. Herr, I., Balemans, L., Böhler, T., Walczak, H., and Debatin, K-M. Monitoring of CD95 (APO-1/Fas) ligand expression in human T-cells by quantitative RT-PCR. Cell Death Differ., 3: 299-305, 1996.
34. Schulze-Osthoff, K., Bauer, M. K. A., Vogt, M., and Los, M. Role of ICE-related and other proteases in Fas-mediated apoptosis. Cell Death Differ., 3: 177-184, 1996.
35. Tewari, M., Quan, L. T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D. R., Poirier, G. G., Salvesen, G. S., and Dixit, V. M. Yama/CPP32β, a mammalian homolog of Ced-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell, 81: 801-809, 1995.
36. Debatin, K-M. Anticancer drugs, programmed cell death and the immune system: defining new roles in an old play. J. Natl. Cancer Inst., 89: 750-751, 1997.
37. Micheau, O., Solary, E., Hammann, A., Martin, F., and Dimanche-Boitrel, M-T. Sensitization of cancer cells treated with cytotoxic drugs to Fas mediated cytotoxicity. J. Natl. Cancer Inst., 89: 783-789, 1997.
38. Müller, M., Strand, S., Hug, H., Heinemann, E-M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., and Galle, P. R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest., 99: 403-413, 1997.
39. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
40. Miyashita, T., and Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human box gene. Cell, 80: 293-299, 1995.
41. Marsters, S. A., Pitti, R. M., Donahue, C. J., Ruppert, S., Bauer, K. D., and Ashkenazi, A. Activation of apoptosis by APO-2 ligand is independent of FADD but blocked by CrmA. Curr. Biol. 6: 750-752, 1996.
42. Higuchi, M., Aggarwal, B. B., and Yeh, E. T. H. Activation of CPP32-like protease in tumor necrosis factor-induced apoptosis is dependent on mitochondrial function. J. Clin. Invest., 99: 1751-1758, 1997.
43. Xiang, J., Chao, D. T., and Korsmeyer, S. J. Bax-induced cell death may not require interleukin 1β-converting enzyme-like proteases. Proc. Natl. Acad. Sci. USA, 93: 14559-14563, 1996.
44. Friedman, H. S., Oakes, W. J., Bigner, S. H., Wikstrand, C. J., and Bigner, D. D. Medulloblastoma: tumor biological and clinical perspectives. J. Neuro-oncol., 11: 1-15, 1991.
45. 2 checkpoint in cancer cells with disrupted p53. J. Natl. Cancer Inst., 88: 956-965, 1996.
46. Liebermann, D. A., Hoffman, B., and Steinman, R. A. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene, 11: 199-210, 1995.
47. Brady, H. J., Salomons, G. S., Bobeldijk, R. C., and Berns, A. J. T cells from bax-α transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53. EMBO J., 15: 1221-1230, 1996.
48. Sheth, K., Jolad, S., Wiedhopf, R., and Cole, J. R. Tumor-inhibitory agents from Hyptis emoryi (Labiatae), J. Pharm. Sci., 61: 1819, 1972.
49. Miles, D. H., Kokpol, U., Zalkow, L. H., Steindell, S. J., and Nabors, J. B. Tumor inhibitors I: preliminary investigation of antitumor activity of Sarracenia flava. J. Pharm. Sci., 61: 613-615, 1974.
50. Sandberg, F., Dutschewska, H., Christov, V., and Spassov, S. Spondiathus preussii var. glaber Engler. Pharmaceutic screening of triterpenes. Acta Pharm. Suec., 24: 253-256, 1987.